Clinical Research Directory
Browse clinical research sites, groups, and studies.
An Open-label Study of CND261 in Seropositive Rheumatoid Arthritis
Sponsor: Candid Therapeutics
Summary
The purpose of the study is to evaluate the safety and efficacy of CND261 in patients with seropositive rheumatoid arthritis.
Official title: A Phase 1b, Open-Label, Multicenter Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Clinical Activity of CND261 in Patients With Seropositive Rheumatoid Arthritis
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
47
Start Date
2025-06-16
Completion Date
2027-06-01
Last Updated
2026-01-26
Healthy Volunteers
No
Conditions
Interventions
CND261
CND261 will be dosed according to the assigned cohort
Locations (6)
Candid Clinical Site
Tbilisi, Georgia
Candid Clinical Site
Chisinau, Moldova
Candid Clinical Site
Auckland, New Zealand
Candid Clinical Site
Bucharest, Romania
Candid Clinical Site
Cluj-Napoca, Romania
Candid Clinical Site
Kyiv, Ukraine